Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.

[1]  J. Baynes,et al.  The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. , 2003, Kidney international.

[2]  J. Baynes,et al.  AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. , 2003, Archives of biochemistry and biophysics.

[3]  M. Nangaku,et al.  Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.

[4]  Alan W. Stitt,et al.  The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. , 2002, Diabetes.

[5]  M. Pischetsrieder,et al.  Analysis of glycated and ascorbylated proteins by gas chromatography-mass spectrometry. , 2002, Journal of agricultural and food chemistry.

[6]  D. A. Maddox,et al.  Prevention of obesity-linked renal disease: age-dependent effects of dietary food restriction. , 2002, Kidney international.

[7]  R. Nagaraj,et al.  Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. , 2002, Archives of biochemistry and biophysics.

[8]  M. Beal.  Oxidatively modified proteins in aging and disease. , 2002, Free radical biology & medicine.

[9]  E. Abdel-Rahman,et al.  Pimagedine: a novel therapy for diabetic nephropathy , 2002, Expert opinion on investigational drugs.

[10]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[11]  T. Metz,et al.  A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.

[12]  A. Heidland,et al.  Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. , 2002, Journal of hepatology.

[13]  D. L. Price,et al.  Chelating Activity of Advanced Glycation End-product Inhibitors* , 2001, The Journal of Biological Chemistry.

[14]  S. Takebayashi,et al.  Obesity Associated with Hypertension or Hyperlipidemia Accelerates Renal Damage , 2001, Pathobiology.

[15]  M. Glomb,et al.  Amides Are Novel Protein Modifications Formed by Physiological Sugars* , 2001, The Journal of Biological Chemistry.

[16]  H Terato,et al.  Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. , 2001, Mutation research.

[17]  Cheolju Lee,et al.  Protein Glycation , 2001, Annals of the New York Academy of Sciences.

[18]  S. Jain,et al.  Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. , 2001, Free radical biology & medicine.

[19]  A. Cerami,et al.  Protein glycation, diabetes, and aging. , 2001, Recent progress in hormone research.

[20]  A. Jenkins,et al.  Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.

[21]  M. Obrenovich,et al.  Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation end products. , 2000, Investigative ophthalmology & visual science.

[22]  W. Keane,et al.  The role of lipids in renal disease: future challenges. , 2000, Kidney international. Supplement.

[23]  B. Nilsson.  Biological effects of aminoguanidine: An update , 1999, Inflammation Research.

[24]  O. Samuelsson,et al.  Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. , 1999, Kidney international. Supplement.

[25]  J. Crowley,et al.  The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. , 1999, The Journal of clinical investigation.

[26]  R. Khalifah,et al.  Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.

[27]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[28]  J. Turtle,et al.  Diabetes in the New Millennium , 1999 .

[29]  S. Horiuchi,et al.  Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. , 1998, Atherosclerosis.

[30]  J. Eaton,et al.  Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. , 1998, Biochemical and biophysical research communications.

[31]  R. Dean,et al.  Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. , 1998, The Biochemical journal.

[32]  T. Saito.  Abnormal lipid metabolism and renal disorders. , 1997, The Tohoku journal of experimental medicine.

[33]  A. Booth,et al.  In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs) , 1997, The Journal of Biological Chemistry.

[34]  F. Hsu,et al.  Mass Spectrometric Quantification of Markers for Protein Oxidation by Tyrosyl Radical, Copper, and Hydroxyl Radical in Low Density Lipoprotein Isolated from Human Atherosclerotic Plaques* , 1997, The Journal of Biological Chemistry.

[35]  N. Hotta,et al.  Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. , 1996, Biochemical and biophysical research communications.

[36]  J. Baynes,et al.  Role of the Maillard Reaction in Diabetes Mellitus and Diseases of Aging , 1996, Drugs & aging.

[37]  T. Lyons,et al.  The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.

[38]  J. Mott,et al.  Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. , 1996, Biochemistry.

[39]  A. Booth,et al.  Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. , 1996, Biochemical and biophysical research communications.

[40]  C. Szabó,et al.  Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. , 1996, Biochemical pharmacology.

[41]  S. Parthasarathy,et al.  Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[42]  A. Loidl-Stahlhofen,et al.  α-Hydroxyaldehydes, products of lipid peroxidation , 1994 .

[43]  W. Keane,et al.  Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure , 1993, Current opinion in nephrology and hypertension.

[44]  J. Baynes,et al.  The reaction of 3-deoxy-D-glycero-pentos-2-ulose ("3-deoxyxylosone") with aminoguanidine. , 1991, Carbohydrate research.